Vaccinul anti-cancer al Moderna-Merck, rezultate pozitive la 1100 de pacienți: speranță nouă în lupta cu boala • Newsweek România

Moderna and Merck's personalized cancer vaccine has shown positive results in a phase 3 trial involving over 1,100 melanoma patients, delaying disease recurrence. The treatment combines mRNA technology with Merck's Keytruda, enhancing immune response against cancer. While results are promising, further monitoring is needed to assess overall survival impact. The companies plan to present detailed findings at an upcoming medical conference and discuss regulatory approval. The vaccine's success could lead to personalized treatments for various cancers, significantly boosting Moderna's stock by over 120%.